Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial
| Autor: | Ingmar Schlampp, Juliane Hörner-Rieber, Clara Köhler, Matthias F. Häfner, Semi Harrabi, Eva Meixner, Tobias Forster, Jürgen Debus, N. Weidner, Adriane Hommertgen, Christof Sohn, Holger Hof, Vanessa Heinrich, David Krug, Michael Golatta, Johannes Hüsing, Laila König, Nathalie Arians, Jörg Heil |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Breast Neoplasms Breast cancer Conventional radiotherapy Quality of life Internal medicine otorhinolaryngologic diseases medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Social functioning business.industry Radiotherapy Planning Computer-Assisted Cosmesis Radiotherapy Dosage Hematology medicine.disease Intensity (physics) Radiation therapy Quality of Life Female Radiotherapy Intensity-Modulated Radiotherapy Conformal business therapeutics Adjuvant |
| Zdroj: | Radiotherapy and Oncology. 163:165-176 |
| ISSN: | 0167-8140 |
| Popis: | Background We recently published 2-year results of the prospective, randomized IMRT-MC2 trial, showing non-inferior local control and cosmesis in breast cancer patients after conventionally fractionated intensity-modulated radiotherapy with simultaneously integrated boost (IMRT-SIB), compared to 3D-conformal radiotherapy with sequential boost (3D-CRT-seqB). Here, we report on 2-year quality of life results. Patients and Methods 502 patients were enrolled and randomized to IMRT-SIB (50.4 Gy in 1.8 Gy fractions with a 64.4 Gy SIB to the tumor bed) or to 3D-CRT-seqB (50.4 Gy in 1.8 Gy fractions, followed by a sequential boost of 16 Gy in 2 Gy fractions). For quality of life (QoL) assessment, patients completed the QLQ-C30 and QLQ-BR23 questionnaires at baseline, 6 weeks and 2 years after radiotherapy. Results Significant differences between treatment arms were seen 6 weeks after radiotherapy for pain (22.3 points for IMRT vs. 27.0 points for 3D-CRT-seqB; p = 0.033) and arm symptoms (18.1 points for IMRT vs. 23.6 points for 3D-CRT-seqB; p = 0.013), both favoring IMRT-SIB. Compared to baseline values, both arms showed significant improvement in global score (IMRT: p = 0.009; 3D-CRT: p = 0.001) after 2 years, with slight deterioration on the role (IMRT: p = 0.008; 3-D-CRT: p = 0.001) and social functioning (IMRT: p = 0.013, 3D-CRT: p = 0.001) as well as the future perspectives scale (IMRT: p = 0.003; 3D-CRT: p = 0.0034). Conclusion This is the first randomized phase III trial demonstrating that IMRT-SIB was associated with slightly superior QoL compared to 3-D-CRT-seqB. These findings further support the clinical implementation of SIB in adjuvant breast cancer treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect